Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Starling Oncology’s financial results for the three months ended September 30, 2026.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Starling Oncology’s financial results for the three months ended September 30, 2026
- Exhibit 99.1 contains the company’s financial figures and additional financial information
- Investors should review the exhibit for revenue, cash position, operating results and liquidity implications
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $169.8M, up 24.3%, led by Specialty Pharmacy revenue $109.3M, up 44%
- Adjusted EBITDA $3.4M versus $(3.5)M, marking a second consecutive positive quarter despite $15.7M net loss
- Capitated revenue up 40%, while MLR worsened to 81.0% from 67.8% year over year
- 2026 guidance narrowed: revenue $650M to $660M, Adjusted EBITDA $4M to $6M, free cash flow $5M to $10M
- Liquidity $36.9M, with $72.5M long-term debt and $5M drawn on the asset-based revolving facility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.